Modulo Bio, Inc.
San Diego, CA
- UEI
- U1TNJGPGNHA9
- CAGE
- 91P31
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 10996 Torreyana Rd, San Diego, CA 92121, USA
- Website
- modulo.bio
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Therapeutic development of an NR1H3-targeting antisense oligonucleotide for ALS | Defense Health Agency | $1,739,076 | |
| Developing an AI-guided triculture platform to model neurohiv specific microglial states under art suppression with… | National Institute of Mental Health | $1,479,470 | |
| Implementing a coupled system of integrative ML modeling and data validation for elucidating microglial therapeutic… | National Institute of Mental Health | $2,885,988 |
About Modulo Bio, Inc.
Modulo Bio, Inc., a San Diego-based for-profit biotech firm, is a federal grant recipient conducting therapeutic development and disease-modeling research for the National Institutes of Health and the Defense Health Agency. The company operates exclusively as a prime recipient on federal research grants; it has no federal contract footprint and no subcontract relationships in the source data.
Modulo Bio's capability portfolio centers on induced pluripotent stem cell (iPSC)-derived disease modeling, machine learning-driven target identification, and translational research in neurodegenerative and neuroinflammatory disease. The company develops multi-cellular in vitro platforms — triculture systems combining iPSC-derived microglia, astrocytes, and neurons — paired with AI/machine learning morphological profiling and multi-omic analysis to classify disease mechanisms and predict therapeutic impact. Recent grant work includes a $1.74 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded May 1, 2026, for therapeutic development of an NR1H3-targeting antisense oligonucleotide targeting amyotrophic lateral sclerosis (ALS), running through April 30, 2028; a $1.479 million Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) awarded March 1, 2026, for AI-guided triculture platform development to model HIV-associated brain injury under antiretroviral therapy suppression, running through February 29, 2028; and a National Institute of Mental Health Project Grant awarded September 15, 2023, for causal machine learning modeling of microglial therapeutic targets in neurodegenerative disease, with ultimate completion August 31, 2025. All work is performed at Modulo Bio's San Diego facility.
Customer concentration is split between two federal grantor agencies — the National Institute of Mental Health (two awards) and the Defense Health Agency (one award) — representing 100% of recent grant activity. Combined obligated dollars across all three grants total $6.1 million. Two awards face ultimate completion within the next twenty-four months, presenting recompete timing in 2025 and 2028.
Quick answers
What is Modulo Bio, Inc.'s UEI?
Modulo Bio, Inc.'s Unique Entity ID (UEI) in SAM.gov is U1TNJGPGNHA9.
What is Modulo Bio, Inc.'s CAGE code?
Modulo Bio, Inc.'s CAGE code is 91P31.
Where is Modulo Bio, Inc. located?
Modulo Bio, Inc.'s physical address in SAM.gov is 10996 Torreyana Rd, San Diego, CA 92121, USA.
Is Modulo Bio, Inc. registered in SAM.gov?
Yes. Modulo Bio, Inc.'s SAM.gov registration is active through May 13, 2027.
What is Modulo Bio, Inc.'s most recent federal award?
Modulo Bio, Inc.'s most recent federal grant award is Therapeutic development of an NR1H3-targeting antisense oligonucleotide for ALS (HT9425261E084), from Defense Health Agency, on May 1, 2026.
On GovTribe
See Modulo Bio, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors